Edition:
United States

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

24.29USD
2:55pm EDT
Change (% chg)

$0.04 (+0.16%)
Prev Close
$24.25
Open
$24.27
Day's High
$24.47
Day's Low
$24.27
Volume
443,253
Avg. Vol
2,091,146
52-wk High
$25.65
52-wk Low
$17.78

Latest Key Developments (Source: Significant Developments)

German patent court issues initial decision
Thursday, 9 Mar 2017 06:35am EST 

Edwards Lifesciences Corp - : District court in Germany ruled that Boston Scientific's lotus valve infringes one of co's patents for transcatheter aortic valves . Edwards is not updating its 2017 financial guidance . Does not presently anticipate disruption to supply of sapien 3 valves to patients . Court also ruled Edwards Sapien 3 valve infringes two of Boston Scientific's patents for outer seals of transcatheter heart valves .Will promptly request an appeal.  Full Article

Boston Scientific receives favorable rulings in Edwards Lifesciences litigation
Thursday, 9 Mar 2017 04:59am EST 

Boston Scientific Corp : Boston scientific receives favorable rulings in edwards lifesciences litigation . German district court of Düsseldorf determined that Edwards Lifesciences infringed two patents of Boston Scientific . Edwards has stated that it will seek permission to appeal this judgment . Edwards Lifesciences and Boston Scientific can appeal each of four decisions as far as district court of Düsseldorf has decided against them .believes that '550 patent will be revoked by European patent office.  Full Article

Edwards Lifesciences says UK patent court issues decision on transcatheter heart valves
Friday, 3 Mar 2017 06:50am EST 

Edwards Lifesciences Corp : UK patent court issues initial decision . Edwards Lifesciences Corp says company is not changing its financial guidance . Edwards Lifesciences Corp - Edwards will promptly request an appeal on specific aspects of decision . Edwards Lifesciences-patents court in uk determined one of boston scientific's patents related to seals for transcatheter heart valves valve is invalid . Edwards Lifesciences Corp - court's decision does not affect commercial availability of sapien 3 valve . Edwards Lifesciences - boston scientific initiated litigation involves multiple patents in multiple venues, to yield court actions over extended period .Edwards Lifesciences Corp - patents court in uk has determined a second patent of Boston Scientific is valid and infringed.  Full Article

Boston Scientific says on Feb. 23 announced voluntary removal of all Lotus Valve devices - SEC filing
Thursday, 23 Feb 2017 08:48am EST 

Boston Scientific Corp : Boston Scientific - on February 23 co announced voluntary removal of all Lotus Valve devices - SEC filing . Boston Scientific Corp - expect to bring the Lotus Valve platform back to market in Europe and other regions in the fourth quarter of 2017 . Boston Scientific - removed Lotus Valve devices from global commercial and clinical sites due to reports of premature release of pin connecting lotus valve to delivery system .Boston Scientific - anticipate filing U.S. premarket approval application submission for Lotus Edge Valve system in Q4, with U.S. launch planned for mid-2018.  Full Article

Boston Scientific enters into second amended, restated credit, security agreement
Friday, 10 Feb 2017 04:53pm EST 

Boston Scientific Corp : Boston Scientific Corp - Boston Scientific Corporation entered into a second amended and restated credit and security agreement - SEC filing . Boston Scientific Corp - amendment to extend term of amended and restated credit agreement, dated as of November 7, 2007 through February 7, 2019 .Boston Scientific Corp - amendment to increase aggregate commitments to $400 million.  Full Article

Boston Scientific sees FY 2017 GAAP earnings per share $0.86 to $0.91
Thursday, 2 Feb 2017 06:30am EST 

Boston Scientific Corp : Boston scientific announces results for fourth quarter and full year ended december 31, 2016 . Q4 gaap earnings per share $0.09 . Sees q1 2017 sales $2.05 billion to $2.1 billion . Q4 sales $2.191 billion versus i/b/e/s view $2.16 billion . Q4 earnings per share view $0.29 -- Thomson Reuters I/B/E/S . Sees fy 2017 gaap earnings per share $0.86 to $0.91 . Sees q1 2017 gaap earnings per share $0.18 to $0.21 . Q4 adjusted earnings per share $0.30 excluding items . Sees fy 2017 revenue $8.675 billion to $8.875 billion . Q1 earnings per share view $0.29 -- Thomson Reuters I/B/E/S . Q4 interventional cardiology worldwide sales $585 million versus $525 million . Fy2017 revenue view $8.78 billion -- Thomson Reuters I/B/E/S . Boston scientific corp - q4 cardiac rhythm management worldwide sales $473 million versus $440 million last year . Boston scientific corp - q1 adjusted earnings, excluding items, are estimated in a range of $0.29 to $0.31 per share . Boston scientific corp sees fy 2017 adjusted earnings, excluding items in a range of $1.22 to $1.26 per share .Fy2017 earnings per share view $1.25 -- Thomson Reuters I/B/E/S.  Full Article

Boston Scientific to buy Neovasc advanced biological tissue capabilities
Friday, 2 Dec 2016 07:00am EST 

Boston Scientific Corp : Boston Scientific announces agreement to acquire Neovasc Advanced Biological tissue capabilities . Boston Scientific - acquisition expected to be immaterial to Boston Scientific earnings per share (EPS) in 2016 and 2017 on an adjusted and GAAP basis .Boston Scientific Corp - Neovasc advanced biological tissue capabilities will be integrated into Boston Scientific structural heart business.  Full Article

Boston Scientific acquires tissue resection device from Distal Access
Tuesday, 15 Nov 2016 06:44am EST 

Boston Scientific Corp : Boston Scientific Corp- specific terms of transaction were not disclosed . Boston Scientific acquires resectr™ tissue resection device from distal access, llc . Boston Scientific Corp - deal is immaterial to earnings per share (eps) in 2016 and 2017 on an adjusted and gaap basis .Boston Scientific acquires resectr™ tissue resection device from distal access, llc.  Full Article

Boston Scientific reports acquisition of the Lumenr tissue retractor system
Thursday, 3 Nov 2016 06:30am EDT 

Boston Scientific Corp : Boston Scientific announces acquisition of the lumenr™ tissue retractor system . Acquisition of lumenr is immaterial to earnings per share (EPS) in 2016 and 2017 on an adjusted and gaap basis . Specific terms of transaction were not disclosed. . Will integrate lumenr system into its endoscopy development program .Boston scientific announces acquisition of the lumenr™ tissue retractor system.  Full Article

EndoChoice holdings agreement with Boston Scientific provides termination fee of $7.95 million under certain circumstances
Tuesday, 27 Sep 2016 09:27am EDT 

Endochoice Holdings Inc :Agreement with Boston Scientific provides termination fee of $7.95 million under certain circumstances.  Full Article

More From Around the Web

U.S. medtech shares gain as investors seek shelter from drug price debate

NEW YORK Investors are seeking shelter in shares of U.S. medical device and supply companies, encouraged by their solid growth prospects and wary that President Donald Trump's criticism of drug prices makes owning pharmaceutical and biotechnology stocks risky.